Premium
Last Chance Therapies and Managed Care Pluralism, Fair Procedures, and Legitimacy
Author(s) -
Daniels Norman,
Sabin James E.
Publication year - 1998
Publication title -
hastings center report
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.515
H-Index - 63
eISSN - 1552-146X
pISSN - 0093-0334
DOI - 10.2307/3527569
Subject(s) - legitimacy , pluralism (philosophy) , law and economics , bone marrow transplantation , medicine , intensive care medicine , health care , transplantation , political science , public relations , law , sociology , surgery , epistemology , politics , philosophy
How can health plans make fair determinations about when “experimental” (and costly) treatments such as high dose chemotherapy with autologous bone marrow transplantation should be covered despite lack of clear clinical consensus about their benefits? Different models for managing “last chance” therapies evolving in some health plans offer promising examples of how issues of fairness and legitimacy in decisionmaking can be addressed.